3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
12
Endocrine
1
CNS
1
Breast
1
Conditions
von Hippel-Lindau Disease
1
Pheochromocytoma
1
Paraganglioma
1
Adenoma, Islet Cell
1
Interventions
Temozolomide
43
Magnetic Resonance Spectroscopy
39
Specimen Handling
29
Radiotherapy
19
Radiation
16
Bevacizumab
14
Biopsy
13
Nivolumab
12
Radiosurgery
11
X-Rays
9
Cyclophosphamide
9
Carboplatin
8
Nuclear Medicine Department, Hospital
7
Irinotecan
7
Ipilimumab
6
Cisplatin
6
AZD 6244
6
Vincristine
5
Topotecan
5
Phantoms, Imaging
5
Lomustine
5
Etoposide
5
CTLA-4 Antigen
5
ulixertinib
4
trametinib
4
pembrolizumab
4
olaparib
4
erdafitinib
4
dinutuximab
4
Surveys and Questionnaires
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
belzutifan
×
CNS
×
30 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA